LFSC vs. BBC
Compare and contrast key facts about F/m Emerald Life Sciences Innovation ETF (LFSC) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).
LFSC and BBC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024. BBC is a passively managed fund by Virtus Investment Partners that tracks the performance of the LifeSci Biotechnology Clinical Trials Index. It was launched on Dec 16, 2014.
Performance
LFSC vs. BBC - Performance Comparison
Loading graphics...
LFSC vs. BBC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | -4.62% | 56.54% | -6.02% |
BBC Virtus LifeSci Biotech Clinical Trials ETF | 10.01% | 63.77% | -14.94% |
Returns By Period
In the year-to-date period, LFSC achieves a -4.62% return, which is significantly lower than BBC's 10.01% return.
LFSC
- 1D
- -0.19%
- 1M
- -3.88%
- YTD
- -4.62%
- 6M
- 18.37%
- 1Y
- 59.47%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
BBC
- 1D
- 1.91%
- 1M
- 0.45%
- YTD
- 10.01%
- 6M
- 58.07%
- 1Y
- 160.96%
- 3Y*
- 25.88%
- 5Y*
- -3.27%
- 10Y*
- 8.62%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
LFSC vs. BBC - Expense Ratio Comparison
LFSC has a 0.54% expense ratio, which is lower than BBC's 0.79% expense ratio.
Return for Risk
LFSC vs. BBC — Risk / Return Rank
LFSC
BBC
LFSC vs. BBC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for F/m Emerald Life Sciences Innovation ETF (LFSC) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LFSC | BBC | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.06 | 4.05 | -1.99 |
Sortino ratioReturn per unit of downside risk | 2.79 | 4.28 | -1.48 |
Omega ratioGain probability vs. loss probability | 1.35 | 1.53 | -0.18 |
Calmar ratioReturn relative to maximum drawdown | 3.42 | 8.09 | -4.68 |
Martin ratioReturn relative to average drawdown | 9.51 | 29.69 | -20.19 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| LFSC | BBC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.06 | 4.05 | -1.99 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.08 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.23 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.94 | 0.12 | +0.81 |
Correlation
The correlation between LFSC and BBC is 0.81, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
LFSC vs. BBC - Dividend Comparison
LFSC has not paid dividends to shareholders, while BBC's dividend yield for the trailing twelve months is around 1.55%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LFSC F/m Emerald Life Sciences Innovation ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BBC Virtus LifeSci Biotech Clinical Trials ETF | 1.55% | 1.70% | 1.00% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.09% | 0.00% | 0.51% |
Drawdowns
LFSC vs. BBC - Drawdown Comparison
The maximum LFSC drawdown since its inception was -29.74%, smaller than the maximum BBC drawdown of -76.85%. Use the drawdown chart below to compare losses from any high point for LFSC and BBC.
Loading graphics...
Drawdown Indicators
| LFSC | BBC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -29.74% | -76.85% | +47.11% |
Max Drawdown (1Y)Largest decline over 1 year | -16.25% | -18.03% | +1.78% |
Max Drawdown (5Y)Largest decline over 5 years | — | -72.58% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -76.85% | — |
Current DrawdownCurrent decline from peak | -11.25% | -29.38% | +18.13% |
Average DrawdownAverage peak-to-trough decline | -8.26% | -37.30% | +29.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.84% | 4.91% | +0.93% |
Volatility
LFSC vs. BBC - Volatility Comparison
The current volatility for F/m Emerald Life Sciences Innovation ETF (LFSC) is 10.08%, while Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a volatility of 13.12%. This indicates that LFSC experiences smaller price fluctuations and is considered to be less risky than BBC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| LFSC | BBC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.08% | 13.12% | -3.04% |
Volatility (6M)Calculated over the trailing 6-month period | 19.95% | 26.96% | -7.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.12% | 40.44% | -11.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 29.27% | 39.31% | -10.04% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.27% | 37.86% | -8.59% |